Intuitive Surgical (NASDAQ:ISRG) Given New $605.00 Price Target at Truist Financial

Intuitive Surgical (NASDAQ:ISRG) had its target price reduced by equities research analysts at Truist Financial from $666.00 to $605.00 in a research note issued on Monday, MarketBeat reports. The brokerage currently has a “buy” rating on the medical equipment provider’s stock. Truist Financial’s target price suggests a potential upside of 25.01% from the company’s current price.

A number of other research analysts also recently weighed in on the company. Leerink Partners lifted their price target on Intuitive Surgical from $490.00 to $548.00 in a report on Monday, January 27th. Barclays upped their target price on Intuitive Surgical from $610.00 to $674.00 in a report on Monday, January 27th. Erste Group Bank raised shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a research report on Tuesday, November 19th. Jefferies Financial Group increased their target price on shares of Intuitive Surgical from $475.00 to $575.00 in a research report on Monday, January 27th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Intuitive Surgical from $575.00 to $675.00 and gave the company an “overweight” rating in a report on Friday, January 24th. One analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $611.86.

Intuitive Surgical Stock Performance

Intuitive Surgical stock opened at $483.95 on Monday. The company has a 50 day moving average price of $565.43 and a 200 day moving average price of $531.90. Intuitive Surgical has a 52 week low of $364.17 and a 52 week high of $616.00. The firm has a market capitalization of $172.37 billion, a price-to-earnings ratio of 75.50, a P/E/G ratio of 5.85 and a beta of 1.43.

Insider Transactions at Intuitive Surgical

In related news, CFO Jamie Samath sold 94 shares of the stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $571.11, for a total transaction of $53,684.34. Following the completion of the sale, the chief financial officer now owns 2,630 shares in the company, valued at $1,502,019.30. This represents a 3.45 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Robert Desantis sold 11,545 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $499.22, for a total value of $5,763,494.90. Following the completion of the sale, the executive vice president now directly owns 5,224 shares in the company, valued at $2,607,925.28. This trade represents a 68.85 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 33,754 shares of company stock worth $17,691,621. 0.90% of the stock is owned by insiders.

Institutional Trading of Intuitive Surgical

A number of hedge funds have recently bought and sold shares of ISRG. Atala Financial Inc acquired a new position in shares of Intuitive Surgical during the fourth quarter valued at about $25,000. Berbice Capital Management LLC acquired a new position in Intuitive Surgical in the 4th quarter valued at approximately $26,000. Parvin Asset Management LLC bought a new stake in shares of Intuitive Surgical in the 4th quarter worth approximately $26,000. BankPlus Trust Department acquired a new stake in shares of Intuitive Surgical during the 4th quarter worth approximately $28,000. Finally, Hurley Capital LLC acquired a new stake in shares of Intuitive Surgical during the 4th quarter worth approximately $28,000. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.